Dermatological Problems of Puberty

    January 2013 in “ Postepy Dermatologii I Alergologii
    Beata Bergler-Czop, Ligia Brzezińska-Wcisło
    Image of study
    TLDR Puberty often causes skin issues like acne and excessive sweating, and treatments require patience as results may vary.
    The 2013 document reviews dermatological issues during puberty, with a focus on acne, which affects 80% to 100% of individuals aged 11 to 30. It discusses the multifactorial pathogenesis of acne, including genetic factors, diet, hormones, and the psychological impact. The review also covers seborrheic dermatitis, hyperhidrosis, and their treatments. It mentions a genetic marker for acne in males and the seasonal improvement of acne lesions. The document further explores the role of sebaceous glands in acne, lists various acne types, and briefly mentions treatment options based on a 2009 consensus. Additionally, it addresses hair-related issues such as dandruff, hair shaft damage, physiological hair loss during puberty, and androgenic alopecia (AGA), including treatments like minoxidil, finasteride, and hair transplants. It emphasizes the need for patience in treatment, as improvements can be temporary.
    Discuss this study in the Community →

    Research cited in this study

    7 / 7 results

    Related Community Posts Join

    6 / 1000+ results

      community Verteporfin trials in hair transplant patients begin

      in Transplants  42 upvotes 2 years ago
      A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.

      community He used Dutasteride for 20 years. Interview

      in Treatment  109 upvotes 1 month ago
      Dutasteride has been used for 20 years with some hair thickness improvement but no dramatic regrowth. The user also experimented with minoxidil, tretinoin, and peptides like BPC 157 for potential benefits in hair density and quality.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 8 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

    Similar Research

    6 / 1000+ results